Hologic, Inc. (NASDAQ:HOLX) Director Sally Crawford sold 13,257 shares of Hologic stock in a transaction on Monday, September 17th. The shares were sold at an average price of $39.54, for a total value of $524,181.78. Following the completion of the transaction, the director now owns 167,701 shares in the company, valued at approximately $6,630,897.54. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Hologic stock traded up $0.19 during midday trading on Thursday, reaching $41.12. The stock had a trading volume of 47,913 shares, compared to its average volume of 1,801,267. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.29 and a quick ratio of 0.99. The firm has a market capitalization of $11.02 billion, a price-to-earnings ratio of 20.25, a PEG ratio of 1.99 and a beta of 0.65. Hologic, Inc. has a 12 month low of $35.10 and a 12 month high of $45.09.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Tuesday, July 31st. The medical equipment provider reported $0.58 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.02. The firm had revenue of $824.00 million during the quarter, compared to analyst estimates of $800.14 million. Hologic had a positive return on equity of 22.18% and a negative net margin of 2.47%. sell-side analysts expect that Hologic, Inc. will post 2.24 EPS for the current year.
Several brokerages have commented on HOLX. Needham & Company LLC lifted their target price on Hologic from $43.00 to $48.00 and gave the stock a “buy” rating in a report on Wednesday, August 1st. BidaskClub raised Hologic from a “hold” rating to a “buy” rating in a report on Wednesday, August 1st. BTIG Research reaffirmed a “buy” rating and set a $47.00 target price on shares of Hologic in a report on Thursday, August 2nd. Deutsche Bank lifted their target price on Hologic from $42.00 to $45.00 and gave the stock a “hold” rating in a report on Wednesday, August 1st. Finally, Canaccord Genuity cut their target price on Hologic from $42.00 to $41.00 and set a “hold” rating on the stock in a report on Tuesday, August 14th. Ten analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Hologic presently has a consensus rating of “Hold” and a consensus price target of $44.47.
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Featured Story: What is the NASDAQ Stock Market?
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.